104691-86-3
104691-86-3 結(jié)構(gòu)式
基本信息
8-PRENYLGENISTEIN
8-Isopentenylgenistein
4',5,7-Trihydroxy-8-prenylisoflavone
4',5,7-Trihydroxy-8-isopentenylisoflavone
3-(4-Hydroxyphenyl)-5,7-dihydroxy-8-(3-methyl-2-butenyl)-4H-1-benzopyran-4-one
5,7-Dihydroxy-3-(4-hydroxyphenyl)-8-(3-methyl-2-butenyl)-4H-1-benzopyran-4-one
4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)-8-(3-methyl-2-buten-1-yl)-
物理化學(xué)性質(zhì)
常見(jiàn)問(wèn)題列表
apoptosis
Lupiwighteone (2-100 μM; 72 hours) shows cytotoxicity towards various cell lines, especially on DU-145 cells and SGC-7901 cells with IC
50
s of 23.7 μM and 21 μM, respectively.
Lupiwighteone (20-60 μM; 48 hours) induces (cell cycle arrest in DU-145 cells.
Lupiwighteone (20-60 μM; 48 hours) induces cells apoptosis.
Lupiwighteone (20-60 μM; 48 hours) decreases the cell cycle-related protein expressions in a dose-dependent manner in DU-145 cells.
Lupiwighteone (20-60 μM; 48 hours) induces a dose-dependent increase in ROS production.
Lupiwighteone up-regulates of cytochrome c and caspase-3, and subsequent cleavage of PARP-1 and down-regulates of the p-Akt/Akt ratio and VEGF expression, suggests the activation of mitochondria-based intrinsic apoptosis in DU-145 cells.
Cell Viability Assay
| Cell Line: | DU-145 cells, C4-2 cells, SGC-7901 cells, Hela cells, HUVEC, MCF-7 cells, CNE cells, Vero |
| Concentration: | 2 μM, 5 μM, 25 μM, 50 μM, 100 μM |
| Incubation Time: | 72 hours |
| Result: | Had inhibition on the survival of many cancer cell lines and HUVEC. |
Cell Cycle Analysis
| Cell Line: | DU-145 cells |
| Concentration: | 20 μM, 40 μM, 60 μM |
| Incubation Time: | 48 hours |
| Result: | Induced cell cycle arrest. |
Apoptosis Analysis
| Cell Line: | DU-145 cells |
| Concentration: | 20 μM, 40 μM, 60 μM |
| Incubation Time: | 48 hours |
| Result: | Induced apoptosis. |
Western Blot Analysis
| Cell Line: | DU-145 cells |
| Concentration: | 20 μM, 40 μM, 60 μM |
| Incubation Time: | 48 hours |
| Result: | Decreased CDK1, 2, 4, 6, cyclinD1, and cyclinB1 protein expression in a dose-dependent manner. |